Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$11.69 USD
+0.13 (1.12%)
Updated May 2, 2024 04:00 PM ET
After-Market: $11.69 0.00 (0.00%) 6:00 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Stoke Therapeutics, Inc. [STOK]
Reports for Purchase
Showing records 1 - 20 ( 89 total )
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Impact on Cognition and Behavior Differentiates STK-001 in the Landscape; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Feeling Pretty STOKed On STK-001 Update; Increasing Target to $17
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AES Data Highlights the Importance of Loading Dose, Indicates Target Engagement in Required Brain Regions in DS Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STK-001 Promises Long Lasting Impact for Dravet Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Steady Sailing Into AES Meeting, 1Q24 Update [3Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Remains Enthusiastic About STK-001s MOA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As We Await Further STK-001 Data Updates, An As Expected 2Q23 Report
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Improvement in Non-Seizure Comorbidities More Critical for STK-001''s Success
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Turns Out STK-001 Dosing May Be More Complicated Than Thought
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Phase 1/2a Update from STK-001-A KOL Perspective
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A